Date and Time: Wednesday, April 21, 2021, 10:30 a.m. ET Presenter: Paul Levesque, President and Chief Executive Officer Webcast Link: https://wsw.com/webcast/bloomburton6/thtx/2799720
Montreal, Canada – April 14, 2021 – Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter ended February 28, 2021 (Q1 Fiscal 2021). “Theratechnologies is at a unique point in its evolution, …Lire la suite
Montreal, Canada – April 12, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 10:30 a.m. …Lire la suite
AACR Poster #1313 – TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several SORT1+ cancers: Click here to view the poster AACR Abstract #1313 – TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several SORT1+ cancers: Click here to view the abstract AACR Poster #1313 Presentation – TH1902, a docetaxel peptide-drug conjugate, shows …Lire la suite
TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone Montreal, Canada – April 10, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the 2021 Annual Meeting of the American Association …Lire la suite
Montreal, Canada – April 1, 2021 – Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced, today that it will report its financial results for the first quarter of fiscal 2021 ended February 28, 2021 on Wednesday, April 14, 2021. A conference call …Lire la suite
John is a Senior Pharmaceutical Industry Leader with extensive experience in Sales, Marketing, Operations and General Management both in the U.S and internationally. He has expertise managing brands across multiple stages of the product life cycle and has launched numerous products in a variety of therapeutic areas. Prior to joining Theratechnologies, John spent 30 years …Lire la suite
Montreal, Canada – March 29, 2021 – Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the addition of two new senior resources to support the growth and development of its commercial and pipeline …Lire la suite
Montreal, Canada – March 24, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors. “This is …Lire la suite